Rice Partnership LLC Has $13.58 Million Stake in Eli Lilly and Company $LLY

Rice Partnership LLC lowered its stake in Eli Lilly and Company (NYSE:LLY) by 4.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 17,802 shares of the company’s stock after selling 812 shares during the quarter. Eli Lilly and Company comprises 1.9% of Rice Partnership LLC’s investment portfolio, making the stock its 17th largest holding. Rice Partnership LLC’s holdings in Eli Lilly and Company were worth $13,583,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the period. OneAscent Wealth Management LLC boosted its holdings in Eli Lilly and Company by 32.0% in the second quarter. OneAscent Wealth Management LLC now owns 359 shares of the company’s stock worth $280,000 after acquiring an additional 87 shares in the last quarter. Sequoia Financial Advisors LLC boosted its holdings in Eli Lilly and Company by 19.0% in the second quarter. Sequoia Financial Advisors LLC now owns 140,201 shares of the company’s stock worth $109,291,000 after acquiring an additional 22,410 shares in the last quarter. Finally, Schnieders Capital Management LLC. grew its stake in Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares during the period. 82.53% of the stock is owned by institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A late‑stage head‑to‑head trial showed Novo Nordisk’s next‑generation obesity drug (CagriSema) failed to achieve non‑inferiority vs. Lilly’s tirzepatide, spurring a sharp selloff in Novo and lifting confidence that Lilly will retain share leadership in the fast‑growing obesity market. Novo’s stumbles burnish Lilly’s widening lead in weight-loss drugs
• Positive Sentiment: The FDA approved and Lilly launched a four‑dose, single‑patient KwikPen for Zepbound (tirzepatide), offering a one‑month‑per‑pen option at the same self‑pay price — a product change that should help adherence/retention and reduce friction for payers and patients. Zepbound now available in multi-dose KwikPen
• Positive Sentiment: Goldman Sachs reiterated a Buy rating and a $1,260 price target, calling Lilly’s 2026 guide conservative while highlighting a diversified pipeline and capital flexibility — an analyst endorsement that supports the stock’s valuation and investor sentiment. Goldman Sachs maintains Buy on Eli Lilly
• Positive Sentiment: Additional pipeline wins: Lilly reported positive combo data (Taltz + Zepbound) in overweight/obese psoriasis patients and expanded licensing activity, underscoring growth avenues beyond obesity/diabetes. These items support longer‑term EPS upside. Pipeline expansion and positive trial data
• Neutral Sentiment: Institutional flows and price targets remain constructive (median analyst targets around $1,250+), which underpins sentiment, but these are already priced into today’s move. Analyst and flow commentary
• Neutral Sentiment: Some commentary notes LLY has recently trailed the S&P 500 on a short‑term basis — a reminder that momentum and macro factors can temper performance even with strong fundamentals. Is Eli Lilly Stock Underperforming the S&P 500?
• Negative Sentiment: High levels of insider/large‑holder sales (noted in recent reports) could be viewed as a cautionary signal for some investors, though context (estate/institutional rebalancing) matters. Watch insider activity for confirmation. QuiverQuant: insider & institutional activity

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,057.38 on Tuesday. The company has a fifty day moving average price of $1,054.73 and a 200-day moving average price of $920.78. The firm has a market cap of $997.49 billion, a price-to-earnings ratio of 46.07, a PEG ratio of 1.17 and a beta of 0.39. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the firm earned $5.32 earnings per share. The firm’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is currently 30.15%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. HSBC reaffirmed a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Rothschild & Co Redburn upped their price objective on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a report on Monday, January 26th. Guggenheim reduced their price objective on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating for the company in a report on Tuesday, January 20th. Finally, Wolfe Research boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,228.54.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.